SciClone set for US$12.8 million SEC foreign bribery settlement
SciClone Pharmaceuticals has agreed in principle to pay US$12.8 million to settle FCPA charges brought by the US Securities and Exchange Commission over conduct in China, the company said in a filing on 10 August.
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.
Subscribe now